The role of CCL2/CCL3-CCR5 pathway in the development of osteoarthritis and its functional MRI monitoring

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039829

Enrollment

Unknown

Registered

2020-11-11

Start date

2020-11-02

Completion date

Unknown

Last updated

2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Group A:Mankin score 0

Group B:Mankin score 1

Group C:Mankin score 2-5

Group D:Mankin score 6-9

Group E:Mankin score 10-14

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The age between 60 and 75; Unilateral total knee replacement was performed.

Exclusion criteria

Exclusion criteria: Rheumatoid arthritis; avascular necrosis; periarticular fracture; current immune modulator therapy or any such therapy within 4 weeks of study procedures; joint infection; neuropathic arthropathy; acromegaly; osteochondromatosis; arthroscopic knee surgery within the previous 12 months; intra articular injection or systemic (oral, intravenous, or intramuscular) steroid within the previous 6 months.

Design outcomes

Primary

Measure	Time frame
CCL2;CCL3;CCR5;ICAM-1;VCAM-1;	—

Countries

China

Contacts

Public ContactSun Shiyu

Shanghai Tenth People's Hospital, Tongji University School of Medicine

sunshiyu0407@126.com+86 17721325518

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026